Oura to acquire AI-native primary care startup Counsel Health for $625M

Eli Lilly's partnership with Counsel Health for GLP-1 prescriptions may be affected by Oura's acquisition of Counsel. Lilly could gain a financial stake in Oura, with a $50 million stock purchase contingent on certain conditions, though these have not yet been met, according to STAT's Elaine Chen.

Oura Health agreed to acquire Counsel Health for $625 million in cash, representing 36% of Oura's last fiscal year's revenue. Counsel provides AI-driven medical chat with licensed doctors, enhancing Oura's smart ring capabilities. The deal is expected to close by the end of 2026, subject to conditions. Oura aims to integrate Counsel's services to offer more comprehensive health solutions, potentially boosting membership retention and IPO prospects.

Oura plans to acquire AI-based healthcare company Counsel Health for $625M in cash. Counsel's platform combines AI chatbots with human physicians for symptom assessment. Oura aims to integrate the service with its smart ring biometric data. The deal is expected to close by year-end, subject to conditions. Oura delayed its IPO in September due to market uncertainty.

Entegris acquired Advanced Abrasives to expand semiconductor materials for AI chips, investing in Taiwan manufacturing. Siemens agreed to buy Lauterbach for $1.6B to bolster semiconductor design and verification. Oura will acquire Counsel Health for $625M to combine biometric data with AI-powered medical care. Cribl acquired Tero to enhance AI observability and monitoring capabilities.

Oura Health is acquiring Counsel Health for $625 million, aiming to integrate AI and wearable data into clinical care. The deal follows a partnership where Counsel's AI chatbot was added to Oura's app. Oura reported $533 million in revenue for Q3 and $1.75 billion for fiscal 2026, up 92% YoY. Both companies plan to continue their direct-to-consumer and enterprise services post-acquisition.

Oura, a smart-ring maker, postponed its $2.2bn IPO on 29 September 2026 due to market uncertainty. The offering included 50 million shares priced between $40 and $44, with most proceeds going to existing investors. Oura planned to use its share for employee tax obligations. The company reported strong revenue growth and profitability but faces market and legal risks. No new IPO date has been set.